Product image of Ilinpru (Linagliptin) supplied by GNH India

Ilinpru

Active Ingredient:
Linagliptin
Origin:
EU

Ilinpru (Linagliptin)

Linagliptin, the active ingredient in Ilinpru, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for systemic use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to improve glycaemic control when used in combination with diet and exercise.

GNH India supplies Ilinpru as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, including Europe and other regulated markets, with a focus on quality assurance and timely reliable logistics.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ilinpru, a DPP‑4 inhibitor, is used in the treatment of type 2 diabetes mellitus to improve glycaemic control.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (combined with metformin): enhances overall glycaemic control when metformin alone is insufficient.
  • Type 2 diabetes mellitus (combined with insulin or other agents): provides additional glucose‑lowering effect in patients requiring multi‑drug regimens.

How It Works

  • Linagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of endogenous incretin hormones such as GLP‑1 and GIP. Elevated incretin levels increase glucose‑dependent insulin secretion from pancreatic β‑cells and suppress glucagon release from α‑cells, resulting in reduced hepatic glucose production and improved post‑prandial glucose control.

Side Effects

Common Side Effects

  • Nasopharyngitis: mild inflammation of the nasal passages and throat.
  • Headache: transient, mild to moderate intensity.
  • Upper respiratory tract infection: symptoms of cough and congestion.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal discomfort: nausea or abdominal pain.
  • Skin rash: mild erythematous lesions.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe hypersensitivity reactions: including angioedema or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous pemphigoid: blistering skin disorder.
  • Acute renal failure: rare but reported in vulnerable patients.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Renal impairment: no dose adjustment required, but monitor renal function regularly.
  • Hepatic impairment: use with caution and assess liver enzymes periodically.
  • Hypersensitivity: discontinue if signs of allergic reaction such as rash, swelling, or difficulty breathing occur.
  • Pregnancy: safety not established; avoid unless potential benefit outweighs risk.
  • Elderly patients: monitor for hypoglycaemia when used with insulin or sulfonylureas.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Linagliptin may interact with several medications. Review the following interaction categories:

Major Interactions (Avoid)

  • Strong P‑gp inhibitors (e.g., itraconazole, clarithromycin): may increase linagliptin exposure and risk of adverse effects.
  • Strong P‑gp inducers (e.g., rifampicin, phenytoin): may reduce linagliptin plasma levels, decreasing efficacy.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed.
  • Metformin: monitor renal function to avoid lactic acidosis.
  • Diuretics: may affect blood glucose control; observe glycaemic response.
  • Antihypertensives: watch for additive blood pressure effects.
  • NSAIDs: potential for renal function changes; assess kidney status.

Frequently Asked Questions

Ilinpru contains the active ingredient linagliptin, a DPP‑4 inhibitor prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4, which normally degrades incretin hormones. By preserving incretins such as GLP‑1 and GIP, it enhances glucose‑dependent insulin release and suppresses glucagon, leading to lower blood glucose levels.

The prescribed dose of Ilinpru is determined by the treating healthcare professional based on individual patient factors, including glycaemic targets, concomitant medications, and overall health status. Patients should follow the prescriber’s instructions exactly.

Safety of linagliptin in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Ilinpru product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other oral antidiabetics, linagliptin offers a once‑daily dosing schedule and does not require dose adjustment in renal impairment, unlike many sulfonylureas or metformin. Its safety profile is generally favourable, though efficacy is similar to other DPP‑4 inhibitors.

Ilinpru should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Ilinpru is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious risks, though rare, include pancreatitis, severe allergic reactions such as anaphylaxis, and hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash with swelling, or signs of liver dysfunction.

Ilinpru is contraindicated in individuals with known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for patients with severe hepatic impairment, and it should be avoided in pregnancy unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT